Click to goto CDHA Public Site Click to goto DivEMS Dal Public Site Click to goto EHS Nova Scotia

Nausea

Date Last Search Run: Feb 01, 2022
Table last updated: Dec 12, 2017
Data last added: May 25, 2017

Recommendation RECOMMENDATION FOR INTERVENTION
STRENGTH OF EVIDENCE FOR INTERVENTION   SUPPORTIVE (Green) NEUTRAL (Yellow) AGAINST (Red) NOT YET GRADED (White)
1 (strong evidence exists)    
2 (fair evidence exists)      
3 (weak evidence exists)  


Interventions

Antidopaminergic
Level Direction Primary Outcome Patient/Process Setting Reference
I Neutral (Yellow) Nausea score Patient In-Patient Fletcher D., Coyne P., Dodson P., Parker G., Wan W., Smith T. A Randomized Trial of the Effectiveness of Topical “ABH Gel” (Ativan®, Benadryl®, Haldol®) vs. Placebo in Cancer Patients With Nausea. J Pain Symp Mngmnt 2014; 48(5):797-803. Medline
I Neutral (Yellow) Reduction nausea Patient In-Patient Murray-Brown F., Dorman S. Haloperidol for the treatment of nausea and vomiting in palliative care patients. Cochrane Database Syst Rev 2015; 11:CD006271. Medline
II Neutral (Yellow) Nausea and Vomiting relief Patient In-Patient Hardy J., O’Shea A., White C. The Efficacy of Haloperidol in the Management of Nausea and Vomiting in Patients with Cancer. J of Pain and Symp Mngmnt 2010; 40(1):111-6. Medline
III Supportive (Green) Nausea control Patient In-Patient Cole R., Robinson F., Harvey L., et al. Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol on a patient with advanced cancer. J of Pain and sym mngmnt 1994; 9(1):48-50. Medline
III Neutral (Yellow) Nausea and vomiting Patient In-Patient Davis M., Hallerberg G. A Systematic Review of the Treatment of Nausea and/or Vomiting in Cancer Unrelated to Chemotherapy or Radiation. J of Pain and Sym mngmnt 2010; 39(4):756-67. Medline

Dimenhydrinate
Level Direction Primary Outcome Patient/Process Setting Reference

Levomepromazine
Level Direction Primary Outcome Patient/Process Setting Reference
III Supportive (Green) Reduction of Nausea Patient In-Patient Eisenchlas J., Garrigue N., Junin M., De Simone G. Lowdose levomepromazine in refractory emesis in advanced cancer patients: an open-label study. Palliative Medicine 2005; 19:71–5. Medline
III Supportive (Green) Patient rating of nausea and/or vomiting Patient In-Patient Kennet A., Hardy J., Shah S., A’Hern R. An open study of methotrimeprazine in the management of nausea and vomiting in patients with advanced cancer. Support Cancer Care 2004; 13:715–21. Medline
III Neutral (Yellow) Reduction in nausea or vomiting Patient In-Patient Glare P., Pereira G., Kristjanson L., et al. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Support Care Cancer 2004; 12:432–40. Medline

Metoclopramide
Level Direction Primary Outcome Patient/Process Setting Reference
III Supportive (Green) Reduction in nausea or vomiting Patient In-Patient Glare P., Pereira G., Kristjanson L., et al. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Support Care Cancer 2004; 12:432–40. Medline

Ondansetron/Granisetron
Level Direction Primary Outcome Patient/Process Setting Reference
III Neutral (Yellow) Reduction in nausea or vomiting Patient In-Patient Glare P., Pereira G., Kristjanson L., et al. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Support Care Cancer 2004; 12:432–40. Medline

Scopolamine
Level Direction Primary Outcome Patient/Process Setting Reference
III Neutral (Yellow) Nausea relief Patient In-Patient Imai K., Ikenaga M., Kodama T., et al. Sublingually administered scopolamine for nausea in terminally ill cancer patients. Support Care Cancer 2013; 21:2777–81. Medline


[ PEP Database - Table of Contents ] [ Email: PEP@Dal.ca ]